|
|
CBMI Related Publications - Steven Potkin Real-time PUB-MED lookup: 73 Results Dropouts and missing data in psychiatric clinical trials.Potkin SG, Siu CO Am J Psychiatry. 2009 Nov;166(11):1295; author reply 1295-6 Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL Prog Neuropsychopharmacol Biol Psychiatry. 2009 Sep 22; Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, Saykin AJ, Orro A, Lupoli S, Salvi E, Weiner M, Macciardi F, Alzheimer's Disease Neuroimaging Initiative PLoS One. 2009 Aug 7;4(8):e6501 Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F Cogn Neuropsychiatry. 2009;14(4-5):391-418 Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C J Clin Psychiatry. 2009 Jun;70(6):801-9 Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO Int J Neuropsychopharmacol. 2009 Oct;12(9):1233-48 Nicotine-induced brain metabolism associated with anger provocation. Gehricke JG, Potkin SG, Leslie FM, Loughlin SE, Whalen CK, Jamner LD, Mbogori J, Fallon JH Behav Brain Funct. 2009 Apr 24;5:19 Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Wu JC, Kelsoe JR, Schachat C, Bunney BG, DeModena A, Golshan S, Gillin JC, Potkin SG, Bunney WE Biol Psychiatry. 2009 Aug 1;66(3):298-301 Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Alzheimer's Disease Neuroimaging Initiative Brain. 2009 May;132(Pt 5):1355-65 Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Zai CC, Tiwari AK, De Luca V, Müller DJ, Bulgin N, Hwang R, Zai GC, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL Eur Neuropsychopharmacol. 2009 May;19(5):317-28 Long-term effects of rivastigmine capsules in patients with traumatic brain injury. Silver JM, Koumaras B, Meng X, Potkin SG, Reyes PF, Harvey PD, Katz DI, Gunay I, Arciniegas DB Brain Inj. 2009 Feb;23(2):123-32 Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative Brain. 2009 May;132(Pt 5):1310-23 Brain-performance correlates of working memory retrieval in schizophrenia: a cognitive modeling approach. Brown GG, McCarthy G, Bischoff-Grethe A, Ozyurt B, Greve D, Potkin SG, Turner JA, Notestine R, Calhoun VD, Ford JM, Mathalon D, Manoach DS, Gadde S, Glover GH, Wible CG, Belger A, Gollub RL, Lauriello J, O'Leary D, Lim KO Schizophr Bull. 2009 Jan;35(1):32-46 A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, Nguyen DD, Mathalon D, Ford J, Lauriello J, Macciardi F, FBIRN Schizophr Bull. 2009 Jan;35(1):96-108 Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium. Potkin SG, Ford JM Schizophr Bull. 2009 Jan;35(1):15-8 Tuning in to the voices: a multisite FMRI study of auditory hallucinations. Ford JM, Roach BJ, Jorgensen KW, Turner JA, Brown GG, Notestine R, Bischoff-Grethe A, Greve D, Wible C, Lauriello J, Belger A, Mueller BA, Calhoun V, Preda A, Keator D, O'Leary DS, Lim KO, Glover G, Potkin SG, FBIRN, Mathalon DH Schizophr Bull. 2009 Jan;35(1):58-66 Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL Schizophr Res. 2008 Dec;106(2-3):248-52 What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A Schizophr Bull. 2008 Aug 22; Smoking to self-medicate attentional and emotional dysfunctions. Gehricke JG, Loughlin SE, Whalen CK, Potkin SG, Fallon JH, Jamner LD, Belluzzi JD, Leslie FM Nicotine Tob Res. 2007 Nov;9 Suppl 4:S523-36 Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Bunney JN, Potkin SG Br Med Bull. 2008;86:23-32 Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Potkin SG, Litman RE, Torres R, Wolfgang CD J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S4-11 New advances in the treatment of schizophrenia. Introduction. Potkin SG J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S1-3 Multivariate analyses suggest genetic impacts on neurocircuitry in schizophrenia. Tura E, Turner JA, Fallon JH, Kennedy JL, Potkin SG Neuroreport. 2008 Apr 16;19(6):603-7 Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controls. Friedman L, Turner JA, Stern H, Mathalon DH, Trondsen LC, Potkin SG Neuroimage. 2008 Apr 15;40(3):1181-94 P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr Psychiatry Res. 2008 Mar 15;158(2):226-47 Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. Potkin SG, Cohen M, Panagides J J Clin Psychiatry. 2007 Oct;68(10):1492-500 Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG J Clin Psychiatry. 2007 Sep;68(9):1333-8 Test-retest and between-site reliability in a multicenter fMRI study. Friedman L, Stern H, Brown GG, Mathalon DH, Turner J, Glover GH, Gollub RL, Lauriello J, Lim KO, Cannon T, Greve DN, Bockholt HJ, Belger A, Mueller B, Doty MJ, He J, Wells W, Smyth P, Pieper S, Kim S, Kubicki M, Vangel M, Potkin SG Hum Brain Mapp. 2008 Aug;29(8):958-72 Methodological considerations for gene expression profiling of human brain. Atz M, Walsh D, Cartagena P, Li J, Evans S, Choudary P, Overman K, Stein R, Tomita H, Potkin S, Myers R, Watson SJ, Jones EG, Akil H, Bunney WE Jr, Vawter MP, Members of National Institute of Mental Health Conte Center and Pritzker Neuropsychiatric Disorders Research Consortium J Neurosci Methods. 2007 Jul 30;163(2):295-309 Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R Lancet Neurol. 2007 Jun;6(6):501-12 Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL J Psychopharmacol. 2007 Sep;21(7):718-27 Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition. Easwaramoorthy B, Pichika R, Collins D, Potkin SG, Leslie FM, Mukherjee J Synapse. 2007 Jan;61(1):29-36 Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. Saigal N, Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J J Nucl Med. 2006 Oct;47(10):1697-706 Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL Int J Neuropsychopharmacol. 2007 Oct;10(5):639-51 Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15 Alpha EEG predicts visual reaction time. Jin Y, O'Halloran JP, Plon L, Sandman CA, Potkin SG Int J Neurosci. 2006 Sep;116(9):1035-44 A general XML schema and SPM toolbox for storage of neuro-imaging results and anatomical labels. Keator DB, Gadde S, Grethe JS, Taylor DV, Potkin SG, FIRST BIRN Neuroinformatics. 2006;4(2):199-212 A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK Schizophr Res. 2006 Jul;85(1-3):254-65 Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J Nucl Med Biol. 2006 Apr;33(3):295-304 A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D Drugs Aging. 2006;23(3):241-9 Imaging phenotypes and genotypes in schizophrenia. Turner JA, Smyth P, Macciardi F, Fallon JH, Kennedy JL, Potkin SG Neuroinformatics. 2006 Winter;4(1):21-49 Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, Kennedy JL Eur Neuropsychopharmacol. 2006 May;16(4):248-59 Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophrenia. Jin Y, Potkin SG, Kemp AS, Huerta ST, Alva G, Thai TM, Carreon D, Bunney WE Jr Schizophr Bull. 2006 Jul;32(3):556-61 Psychometric evaluation of the Readiness for Discharge Questionnaire. Potkin SG, Gharabawi GM, Greenspan AJ, Rupnow MF, Kosik-Gonzalez C, Remington G, Ruetsch C, Revicki D Schizophr Res. 2005 Dec 15;80(2-3):203-12 Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Lane RM, Potkin SG, Enz A Int J Neuropsychopharmacol. 2006 Feb;9(1):101-24 Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Shinkai T, De Luca V, Hwang R, Matsumoto C, Hori H, Ohmori O, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Nakamura J, Kennedy JL Neurosci Lett. 2005 Nov 11;388(2):116-20 Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Potkin SG, Keck PE Jr, Segal S, Ice K, English P J Clin Psychopharmacol. 2005 Aug;25(4):301-10 A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J Nat Med. 2005 May;11(5):551-5 Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL Psychopharmacology (Berl). 2005 Aug;181(1):179-87 Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. Chattopadhyay S, Xue B, Collins D, Pichika R, Bagnera R, Leslie FM, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J J Nucl Med. 2005 Jan;46(1):130-40 The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R Schizophr Bull. 2004;30(3):577-86 Gender: a major determinant of brain response to nicotine. Fallon JH, Keator DB, Mbogori J, Taylor D, Potkin SG Int J Neuropsychopharmacol. 2005 Mar;8(1):17-26 Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ Schizophr Res. 2004 Feb 1;66(2-3):101-13 Alzheimer disease and other dementias. Alva G, Potkin SG Clin Geriatr Med. 2003 Nov;19(4):763-76 Hostility differentiates the brain metabolic effects of nicotine. Fallon JH, Keator DB, Mbogori J, Turner J, Potkin SG Brain Res Cogn Brain Res. 2004 Jan;18(2):142-8 Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG Curr Med Res Opin. 2003;19(8):707-14 Memory for emotional stimuli in patients with Alzheimer's disease. Fleming K, Kim SH, Doo M, Maguire G, Potkin SG Am J Alzheimers Dis Other Demen. 2003 Nov-Dec;18(6):340-2 Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Potkin SG, Alphs L, Hsu C, Krishnan KR, Anand R, Young FK, Meltzer H, Green A, InterSePT Study Group Biol Psychiatry. 2003 Aug 15;54(4):444-52 Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR Arch Gen Psychiatry. 2003 Jul;60(7):681-90 Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D Arch Neurol. 2003 Jun;60(6):843-8 Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL J Clin Psychiatry. 2003 May;64(5):580-8 Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K, Ziprasidone in Mania Study Group Am J Psychiatry. 2003 Apr;160(4):741-8 The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Potkin SG Int Psychogeriatr. 2002;14 Suppl 1:7-26 MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. Molnar M, Potkin SG, Bunney WE, Jones EG Biol Psychiatry. 2003 Jan 1;53(1):39-47 Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group Arch Gen Psychiatry. 2003 Jan;60(1):82-91 Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Potkin SG, Thyrum PT, Bera R, Carreon D, Alva G, Kalali AH, Yeh C Clin Ther. 2002 Nov;24(11):1809-23 Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Potkin SG, Anand R, Alphs L, Fleming K Schizophr Res. 2003 Jan 1;59(1):59-66 Pharmacogenomics in schizophrenia: the quest for individualized therapy. Basile VS, Masellis M, Potkin SG, Kennedy JL Hum Mol Genet. 2002 Oct 1;11(20):2517-30 Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. Potkin SG, Alva G, Keator D, Carreon D, Fleming K, Fallon JH Brain Res. 2002 Sep 27;951(1):87-95 Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Albert KA, Hemmings HC Jr, Adamo AI, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE Jr, Greengard P Arch Gen Psychiatry. 2002 Aug;59(8):705-12 Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Potkin SG, Thyrum PT, Alva G, Carreon D, Yeh C, Kalali A, Arvanitis LA, Pharmacokinetic Study Group J Clin Psychopharmacol. 2002 Apr;22(2):174-82 The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA J Clin Psychopharmacol. 2002 Apr;22(2):121-30 A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH Am J Psychiatry. 2002 Feb;159(2):227-37 |
|||||||||||||||||